2018
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
Ramakrishna N, Temin S, Chandarlapaty S, Crews JR, Davidson NE, Esteva FJ, Giordano SH, Kirshner JJ, Krop IE, Levinson J, Modi S, Patt DA, Perlmutter J, Winer EP, Lin NU. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. Journal Of Clinical Oncology 2018, 36: jco.2018.79.271. PMID: 29939840, DOI: 10.1200/jco.2018.79.2713.Peer-Reviewed Original ResearchConceptsHuman epidermal growth factor receptorAdvanced breast cancerBrain metastasesBreast cancerEpidermal growth factor receptorGrowth factor receptorSystemic therapyLocal therapyAdvanced human epidermal growth factor receptorASCO Clinical Practice Guideline UpdateHER2-positive advanced breast cancerClinical Practice Guideline UpdateAppropriate local therapyBest supportive careWhole brain radiotherapyProgression-free survivalSize of metastasesFactor receptorExpert panelPresence of symptomsRoutine magnetic resonanceOutcomes of interestStrong quality evidenceMagnetic resonance imagingAdvocacy experts
2014
Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Burstein HJ, Temin S, Anderson H, Buchholz TA, Davidson NE, Gelmon KE, Giordano SH, Hudis CA, Rowden D, Solky AJ, Stearns V, Winer EP, Griggs JJ. Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update. Journal Of Clinical Oncology 2014, 32: 2255-2269. PMID: 24868023, PMCID: PMC4876310, DOI: 10.1200/jco.2013.54.2258.Peer-Reviewed Original ResearchConceptsAdjuvant endocrine therapyHormone receptor-positive breast cancerReceptor-positive breast cancerClinical practice guidelinesAdjuvant tamoxifenEndocrine therapyAromatase inhibitorsBreast cancerPractice guidelinesClinical Oncology Clinical Practice GuidelineOncology Clinical Practice GuidelineASCO Clinical Practice GuidelineYears of tamoxifenContralateral breast cancerYears of therapyRandomized clinical trialsBreast cancer recurrenceTreatment of womenOutcomes of interestTamoxifen useAdjuvant therapyASCO guidelinesAdverse eventsTamoxifen treatmentDisease recurrence
2002
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002.
Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, Mamounas EP, Gralow J, Goldstein LJ, Pritchard KI, Braun S, Cobleigh MA, Langer AS, Perotti J, Powles TJ, Whelan TJ, Browman GP. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. Journal Of Clinical Oncology 2002, 20: 3317-27. PMID: 12149306, DOI: 10.1200/jco.2002.06.020.Peer-Reviewed Original ResearchConceptsHormone receptor-positive breast cancerReceptor-positive breast cancerAromatase inhibitorsBreast cancerASCO Health Services Research CommitteeAdjuvant breast cancer settingClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalAdjuvant hormonal therapyBreast cancer settingCancer-specific survivalBreast cancer incidenceIndividual health care providersHealth care providersAmerican SocietyOutcomes of interestNet health benefitAdjuvant tamoxifenASCO panelAdjuvant therapyHormonal therapyOverall survivalStandard therapyAmerican Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.
Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG, Burstein HJ, Eisen A, Lipkus I, Pfister DG. American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. Journal Of Clinical Oncology 2002, 20: 3328-43. PMID: 12149307, DOI: 10.1200/jco.2002.06.029.Peer-Reviewed Original ResearchConceptsBreast cancer risk reductionUse of tamoxifenCancer risk reductionBreast cancer riskCancer riskASCO Health Services Research CommitteeBreast cancer risk reduction strategiesAromatase inhibitionCancer risk reduction strategiesClinical Oncology technology assessmentEvidence-based technology assessmentsHealth Services Research CommitteeBreast cancer-specific survivalHigher breast cancer riskUse of raloxifeneCancer-specific survivalHormone replacement therapyBreast cancer incidenceHealth benefitsGreater clinical benefitOverall health benefitsAmerican SocietyOutcomes of interestNet health benefitRisk reduction